FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology, and concerns the treatment of neoplastic disease. To do this, enter the pharmaceutical composition comprising the antibody to IL-1α.
EFFECT: this ensures the stabilization of progressive cancer resistant to other types of anticancer therapy.
7 cl, 6 ex
| Title |
Year |
Author |
Number |
| CACHEXIA THERAPY |
2012 |
|
RU2622021C2 |
| TREATMENT OF PURULENT HIDRADENITIS |
2018 |
- Kim Stanley A.
- Giamarellos-Bourboulis Evangelos
|
RU2772202C2 |
| TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF |
2013 |
|
RU2671955C2 |
| ANTIBODIES TO INTERLEUKIN-1ALPHA, AND APPLICATION METHODS THEREOF |
2013 |
|
RU2666915C2 |
| ANTIBODIES TO INTERLEUKIN-1α, AND ITS APPLICATION METHODS |
2009 |
|
RU2498998C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF |
2020 |
- Dejli, Kristofer
- Terston, Gevin
- Papadopulos, Nikolas
|
RU2821548C2 |
| TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT |
2018 |
- Evans, Elizabet
- Smit, Ernest S.
- Zauderer, Moris
|
RU2783535C2 |
| BISPECIFIC ANTIBODY MOLECULES AND ANTIGEN TRANSFECTED T-CELLS, AND THEIR USE IN MEDICINE |
2013 |
- Burken Karol
- Kastoldi Raffaella
- Endres Shtefan
- Klyajn Kristian
- Kobold Sebastyan
- Niderfellner Gerkhard
- Zustmann Klaudio
|
RU2693264C2 |
| ANTIBODY AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) AND APPLICATION THEREOF |
2015 |
|
RU2661678C1 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MUC16 AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB |
2020 |
- Kirshner, Dzhessika R.
- Krouford, Elison
- Chiu, Danika
|
RU2822091C2 |
